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Dystrophinopathies are inherited diseases caused by mutations in the dystrophin (DMD)
gene for which testing is mandatory for genetic diagnosis, reproductive choices and
eligibility for personalized trials. We genotyped the DMD gene in our Italian cohort of 1902
patients (BMD n = 740, 39%; DMD n =1162, 61%) within a nationwide study involving 11
diagnostic centers in a 10-year window (2008–2017). In DMD patients, we found deletionsMarch 2020 | Volume 11 | Article 1311
Neri et al. DMD Gene Mutations in Italy
Frontiers in Genetics | www.frontiersin.orgin 57%, duplications in 11% and small mutations in 32%. In BMD, we found deletions in
78%, duplications in 9% and small mutations in 13%. In BMD, there are a higher number
of deletions, and small mutations are more frequent than duplications. Among small
mutations that are generally frequent in both phenotypes, 44% of DMD and 36% of BMD
are nonsense, thus, eligible for stop codon read-through therapy; 63% of all out-of-frame
deletions are eligible for single exon skipping. Patients were also assigned to Italian
regions and showed interesting regional differences in mutation distribution. The full
genetic characterization in this large, nationwide cohort has allowed us to draw several
correlations between DMD/BMD genotype landscapes and mutation frequency, mutation
types, mutation locations along the gene, exon/intron architecture, and relevant protein
domain , w i th e ffec ts on popu la t ion genet ic character is t ics and new
personalized therapies.Keywords: dystrophin, muscular dystrophy, nationwide study, exon skipping therapy, read-through therapyINTRODUCTION
Dystrophin gene (DMD OMIM *300377) mutations account for
different allelic conditions: Duchenne muscular dystrophy
(DMD, OMIM *310200), which is the most common form of
muscular dystrophy in childhood, occurring in 1 in 3,500 to
5,000 male births, and Becker muscular dystrophy (BMD,
OMIM *300376), a milder form, with an incidence of 1 in
20,000 live male births (Mah, 2016).
Allelic dystrophin mutations can also give rise to isolated
cardiac involvement, or X-linked dilated cardiomyopathy
(XLDC, OMIM*302045) (Neri et al., 2012).
DMD gene mutations cause reduction (BMD) or complete
absence (DMD) of the dystrophin protein (DYS), which
expression is vital for a series of striated muscles and brain
functions (Muntoni et al., 2003). The phenotype of DMD/BMD
is characterized by a delayed achievement of motor milestones
and by an elevated level of the muscle isoform, creatine
phosphokinase (M-CK), present also at birth, which rises as a
direct consequence of muscle damage.
The dystrophin gene (DMD), with its 79 constitutive exons,
and at least other 7 alternatively-used exons, is the largest known
human gene, spanning 2.2 Mb of genomic DNA (Muntoni et al.,
2003). Due to its enormous size, the gene mutation rate is high,
and 1 out of 3 are de novomutations. Gross rearrangements (i.e.,
deletions and duplications) account for the majority of cases
(75%) and the remaining mutations are small mutations (25%)
or rarely deep intronic CNVs/small mutations (see many reports
as cited in Leiden online variation database https://databases.
lovd.nl/shared/genes/DMD) (Artsma-Rus et al., 2006; White and
den Dunnen, 2006).
Mutations can occur everywhere in the gene, but few
mutational hot spots are known: deletions cluster preferentially
between exons 45 to 55 and duplications in the region of exons 2
to 10 (Ankala et al., 2012; White et al., 2006). An additional hot
spot occurs at the 5′ end of the gene involving intron 7. It has
been previously reported that deletions are mostly maternally
inherited, whereas duplications originate from the grand2paternal germline, therefore presenting more frequently as
familial cases and with a higher recurrence risk (Hu et al.,
1990; White et al. , 2006). Very rare DMD complex
rearrangements are described, such as intronic CNVs causing
new cryptic splice sites which induce pseudoexon shuffling into
the transcript or exon orientation inversion leading to exon
skipping. These atypical genomic configurations escape the
routine DNA-based diagnostic procedures (either MLPA or
sequencing) and could be identified only by RNA studies
(Ferlini et al., 2013).
RNA studies are also of relevance in cases of mutations with
uncertain pathogenic meaning, like missense, synonymous or even
nonsense mutations, whichmay occur in exonic splicing enhancers/
silencers, therefore affecting splicing choices. The study of the RNA
profile in skeletal muscle/myogenic cells might therefore be
compulsory in some cases (Falzarano et al., 2015).
The genotype-phenotype correlation generally follows the
frame rule: mutations (all types) that disrupt the translational
open reading frame cause almost complete protein absence and
lead to the severe DMD phenotype, whereas mutations
maintaining the reading frame allow a shorter protein
production and are associated with the milder BMD clinical
phenotype (Monaco et al., 1988).
Exceptions to the rules have however been described and hold
approximately for 10% of DMD/BMD cases (Bladen et al., 2015).
Alternative splicing, spontaneous exon skipping or alternative
translation initiation mechanisms play a role in these exceptions,
but still, the explanation of many of these events remains unknown
(Gualandi et al., 2009; Wein et al., 2014; Tuffery-Giraud et al., 2017).
Understanding the type and frequency of patient-specific
mutations is mandatory for genetic diagnosis and counseling
and for establishing the eligibility for mutation-specific clinical
trials that, in the last years, increasingly target specific groups of
mutations, such as deletions amenable to skipping individual
exons or nonsense mutations (https://clinicaltrials.gov/).
Molecular analysisof thehugeDMDgene is routinelyperformed
in many laboratories worldwide using different techniques and
specific guidelines have been defined (Abbs et al., 2010).March 2020 | Volume 11 | Article 131
Neri et al. DMD Gene Mutations in ItalyWe present here the results of genetic analysis in a large Italian
cohort of 1902 genotyped patients diagnosed in a temporal
window of 10 years in 11 Italian diagnostic centers belonging to
the EURO-NMD (https://ern-euro-nmd.eu) European Reference
Center (as Health Care Providers or HCPs). This represents the
first report on Italian dystrophinopathies and the largest cohort of
proband male patients with independent mutations reported until
now. Such a genetic DMD mapping drives many considerations
and reflection on dystrophinopathy diagnosis, prevention,
and therapy.MATERIALS AND METHODS
Ethical Aspects
This is a collaborative effort including the 11 reference centers
(see the full list in Table 1) providing dystrophin genetic analysis
in Italy. Ethical consent was collected in each center as part of the
routine diagnostic procedures for DMD genetic diagnosis. Data
analyses in this paper were carried out based on the EU project
BIO-NMD Ethical Approval N. 9/2005.
This study was performed based on the RARER (Emilia
Romagna Region Grant, Area 1A) project and evaluated and
approved by the Local Ethical Committee of the University
Hospital of Ferrara, Italy (ethical approval n. 139–2012, date of
approval December, 20, 2012). Written informed consent was
obtained from both patients and parents either for study
participation and for publication aims.
Enrolled Patients
Enrollment criteria for the study were the following: i) male
patients with a clinical diagnosis of dystrophinopathy (DMD or
BMD) with or without muscle biopsy; ii) DMD mutation (any
type) identified; iii) genetic diagnoses made between the 1st of
January 2008 and the 31st of December 2017. Of the 1902 index
patients who fulfilled the inclusion criteria in the 11 centers, 1162
were clinically classified as DMD and 740 as BMD (see Table 1).
Categorization of patients as DMD or BMD was based on
clinical criteria (Birnkrant et al., 2018)
Laboratory Methods
The genetic diagnosis was performed by deletion and duplication
detection (Multiple Ligation Probe Amplification, LOG-PCR,
multiplex PCR) in the majority of cases as the first approach and
then by sequencing analysis (Sanger method, Multiplicom Next
Generation Sequencing, and Motorplex).
Genomic DNA was extracted from EDTA-preserved whole
blood using either automated or manual methods following
manufacturer's instructions
MLPA assay was performed using the P034/P035 DMD Kit
(MRC Holland). Amplified products were analyzed using an ABI
3100 analyzer (Applied Biosystems, Foster City, CA) with
GeneMarker software version 1.5.1 (Soft Genetics, State
College, PA). Peak heights were normalized, and a deletion or
duplication was identified when the normalized peak ratio value
was 0 or 2 for male patients. (Schouten et al., 2002; Schwartz andFrontiers in Genetics | www.frontiersin.org 3Dunø, 2004; Vengalil et al., 2017). When a single-exon deletion
or duplication was observed, Sanger sequencing was used
for verification.
The LOG-PCR (Trimarco et al., 2008) is a new tool for
complete screening of DMD exons. This method uses only 4
quantitative multiplex PCRs, which are run under the same
reaction and cycling conditions, and can also be useful for
assessing carrier status when the mutation is known. It detects
deletions and duplications and provides a proof of principle for
higher-throughput multiplex PCR methods.
In theOspedaleMaggiore PoliclinicoMilano laboratory,MLPA
was used as the first screening for deletions or as confirmation of
positive results by home-made quantitative multiplex-PCR.
For detection of small mutations, analysis was carried out by
Sanger: PCR primers (provided by request) were designed by
Vector NTI Advance (Informax Frederick, Maryland USA)
analysis software to amplify all coding exons and flanking
intronic sequences of DMD (RefSeq NM_004006.2). PCR
products generated using Taq DNA polymerase (Roche,
Indianapolis, IN) were sequenced in both forward and reverse
orientations using the BigDye Terminator Cycle Sequencing kit
(version 1.1) and analyzed on a sequencer. Patient sequence data
were aligned for comparison with corresponding wild-
type sequence.
In the Ferrara center for Next Generation Sequencing (NGS),
the library preparation was done with the DMDMASTR™ assay
(Multiplicom, Niel Belgium) according to the manufacturer's
instructions. All 79 exons were sequenced in 118 amplicons
spanning 280 to 400 bp and with a minimal coverage per allele of
50×. Sequencing was done on MySeq (Alame et al., 2016).
In the Genoa, Roma UILDM, and Cagliari centers for NGS
sequencing, the amplification of coding regions and flanked
intronic regions (10 bp) of DMD gene was performed by
Ampliseq method (reference sequence NM_004006.2);
sequencing was performed by IonTorrent method on PGM
platform. The data analysis was then performed by CLC
Genomics Workbench e Ion Reporter software. All mutations
were validated by Sanger sequencing.
Motorplex is a targeting NGS workflow created for diagnosis
of genetic myopathies (Savarese et al., 2014). More than 95% of
targeted nucleotides were read at a 100× depth and a 500× depth
was obtained for 80% of these. MotorPlex may discover low-
allelic fraction variants in single samples, such as in somatic
mosaicisms. The MotorPlex is likewise the cheapest genetic test
ever presented that is able to screen 93 complex conditions at the
cost of a few PCR reactions.
Data Analysis
The results were analyzed by looking for frequency distribution
of deletions, duplications, and small mutations in both DMD and
BMD patients.
Within deletions and duplications, we analyzed those
occurring in single or multiple exons, the last either being in-
frame or out-of-frame. Deletion or duplication sites were thus
considered depending on the adjacent intron length and on the
involvement of regions encoding crucial proteins domains. SomeMarch 2020 | Volume 11 | Article 131
TABLE 1 | Centers of the Italian network and genotypic data of the patients. All the variants identified by the centers were submitted to the LOVD database (www.lovd.nl).
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GENOVA Paediatric Neurology and Muscular Diseases Unit,
University of Genoa and G. Gaslini Institute
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PISA IRCCS Fondazione Stella Maris Department of Molecular
Medicine
74 26 48 63 20
MILANO Laboratory of Medical Genetics Foundation IRCCS Ca'
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CAGLIARI
25 14 11 13 6
Unit of Neuromuscular Diseases, Oasi Research Institute-IRCCS,
TROINA (En)
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FERRARA Unit of Medical Genetics, University of Ferrara 769 530 239 404 253
TOTAL 1902 1162 740 1242 667
Neri et al. DMD Gene Mutations in Italyevolutionary aspects of the giant introns composing the DMD
gene were also highlighted and discussed. Within the small
mutation group, we explored the frequency of small mutations
occurring in in-frame and out-of-frame exons.
We categorized our patients based on their place of birth and
consequently assigned them to specific Italian regional areas.
North, Center, South (including Sicily) and Sardinia were
considered separately because of their known different genetic
profiles and ethnic characteristics (Capocasa et al., 2014).
Finally, since during the last decade there have been an
increasing number of new therapeutic approaches targeting
specific groups of mutations with some drugs that already
received the approval of regulatory authorities in the USA and/
or in Europe, we also have identified the frequency of mutations
amenable for personalized therapies.
More specifically, we identified the frequency of nonsense
mutations eligible for stop codon readthrough therapy, and theFrontiers in Genetics | www.frontiersin.org 5frequency of the groups of deletions amenable for skipping of
exon 44, 45, 51, and 53, which are/were in clinical trials.RESULTS
A DMDmutation was identified in 1902 patients. Table 1 shows
the genotypic data of the Italian cohort. Figure 1 shows the
mutation type distribution in DMD and BMD Italian patients.
Deletions were the most frequently occurring mutations,
accounting for 57% of mutation types in the DMD patients
(Figure 1A) and 78% in the BMD patients (Figure 1B).
Duplications occurred at a similar rate in both DMD (11%)
and BMD patients (9%). Small mutations occurred in 32% of
DMD and 13% of BMD patients.
Among all small mutations, nonsense were the most frequent
in both DMD (14%) and in BMD (5%), followed byFIGURE 1 | Overview of mutations distribution in DMD and BMD patients from Italy. Deletions were the most frequent occurring mutations, accounting for 57% of
mutation types in the DMD patients (A) and in 78% in the BMD patients (B), duplications occurred at a similar rate in both DMD (11%) and BMD patients (9%), small
mutations occurred in 32% of DMD and 13% of BMD patients. Among all mutation types, nonsense are the most frequently occurring small changes both in DMD
(14%) and in BMD (5%), followed by frameshifting (DMD 11%, BMD 2%), and splicing canonical sites (DMD 5%, BMD 2 %), missense (DMD 1%, BMD 3%).
Mutations occurring in splicing consensus sequences are 1% both in DMD and in BMD.March 2020 | Volume 11 | Article 131
Neri et al. DMD Gene Mutations in Italyframeshifting (DMD 11%, BMD 2%), splicing canonical sites
(DMD 5%, BMD 2 %), and missense (DMD 1%, BMD 3%).
Mutations occurring in splicing consensus sequences were 1% in
both DMD and in BMD. Not unexpectedly, missense mutations
were more frequently found in BMDs, which also show less
nonsense changes than DMD. A few (4) proven pathogenic
synonymous mutations were found (Supplementary Table 1).
Deletions
The most common single exon deletion in DMD was exon 45,
while the most common multiple exon deletion was 45 to 52.
Deletions were very heterogeneous and non-randomly
distributed, occurring in the two known hot spots at the 5′ and
3′ end of the gene (Supplementary Figure 1).
Single exon deletion was never found in 29 in-frame exons
(namely exons 3, 4, 9, 15, 16, 23, 25, 26, 28, 29, 32, 33, 34, 35, 36,
37, 38, 39, 41,42, 49, 60, 64, 71, 72, 73, 74, 75, 79) both in DMD
and BMD. A few (12) out-of-frame exons (7, 11, 20, 59, 62, 65,
66, 67, 69, 70, 76, 77) were also never the site of single
exon deletions.
Duplications
The most common single exon duplication occurred in exon 2
while the most common multiple exon duplication was in
exon 3 to 7. The major 5′ breakpoints occurred within intron
M1 or 2 for single duplications and within intron 2 (5′ end)
and intron 7 (3′ end) for the multiple exon duplications
(Supplementary Figure 1). Since genomic architecture of
duplications cannot be identified neither by MLPA or CGH
testing, the frame rule is not unambiguously applicable to
these rearrangements to predict, for instance, possible self-
reframing capability.
Similarly to deletions, n = 35 in-frame exons were never the
site of isolated duplications (neither in DMD nor in BMD), as in-
frame exons 4, 9, 10, 13, 14, 15, 23, 24, 25, 26, 27, 28, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 42, 47, 48, 49, 60, 64, 71, 72, 73, 74,
75, 79 and n = 26 out-of-frame exons 6,7,17,19, 20, 43, 46,51, 52,
53, 56, 57, 58, 59, 61, 62, 63, 65, 66, 67, 68, 69, 70, 76, 77, 78 also
were never singly duplicated.
There were a few in-frame exons which were only singly
deleted (exons 3, 16, 29, 41) or singly duplicated (exons 10, 13,
14, 24, 27, 30, 31, 40, 47, 48) and some out-of-frame exons only
singly deleted (11) or singly duplicated (exons 6, 17,19, 43, 46, 51,
52, 53, 56, 57, 58, 61, 63, 68, 78). In general, 41 DMD exons are
never the site of isolated deletions, whilst 61 DMD exons are
never the site of isolated duplications.
This means that single-exon rearrangements affect
approximately less than a half of the 79 DMD exons and
conversely, the majority of large rearrangements involve
multiple exons.
Small Mutations
The rate of small mutations in DMDs was 32%. Among these,
nonsense was the most frequently occurring class of mutation at
44%, followed by frameshifting (34%), splicing canonical sites
(14%), splicing consensus (4%), and the rare missense (4%).Frontiers in Genetics | www.frontiersin.org 6BMDs show 13% of small mutations (Figure 1).
Distribution of the small changes was along the whole gene,
without hot spots, with a rather homogenous spectrum of change
types; among small mutations in BMD nonsense were the
majority (36%) followed by missense (26%), splicing canonical
sites (15%), splicing consensus sequence (7%), frameshifting
(13%) and missense (3%). Compared to other reports,
missense variations were very frequent in the Italian BMDs. In
BMDs, also the small changes distribution was random without
preferred sites.
Figure 2 shows the localization of small changes (all) in in-
frame or out-of-frame exons both in DMD and BMD patients.
The majority of small changes in DMD (68.5%, n = 211) locates
in out-of-frame exons, while only 31.4% (n = 97) locates in in-
frame exons, thus predicting a general low self-reframing
capability. This type of change is not homogenously
distributed since nonsense mutations occur in 62% of in-frame
exons compared to 51% in out-of-frame exons, frameshifting
changes are more frequent in out-of-frame exons (43% vs 36%
in-frame) and the missense are 2% in in-frame vs 6%
out-of-frame.
In BMDs, small changes are prevalent in in-frame exons
(58.3%, n = 42) compared to out-of-frame (41.6%, n = 30) exons.
Nonsense mutations occur much more frequently, almost
double, in in-frame exons (57% vs 30%), frameshifting changes
are equally distributed (17%) and missense mutations are more
represented in out-of-frame exons (53% vs 19%). We also
analyzed the splicing mutations involving the canonical splice
sites, both donor and acceptor, and for this specific group of
mutations it is difficult to predict the exact consequences on
splicing patterns and therefore on framing of the exons involved.
It is well known from literature that the effect of mutations at the
canonical splice site usually lead to single exon skipping
(upstream or downstream exon) but if there is a strong
cryptic site in the neighborhood it can be used instead
(Habara et al., 2009; Abramowicz and Gos, 2019) (see the
complete list of splicing mutations in DMD and BMD in
Supplementary Table 2).
Regional DMD Mutation Distribution
Deletions had a similar distribution in the North and South
regions (51%–59% respectively in DMDs and 65%–70% in
BMDs) while in Central Italy they were more frequent both in
DMD (77%) and in BMD (91%) (Figure 3).
Duplications had a similar distribution in North and South
regions (14%–11% DMD and 12% BMD while in Central Italy
they were less frequent (8% in DMD and 4% in BMD).
Small mutations were differently distributed in DMDs.
Nonsense mutations account for only 6% in the South region
compared to the 20% in the North, with frameshifting around
8% in the North and 16% in the South. In Central Italy, small
mutations were much lower.
Data for Sardinia may suffer due to the low number of
patients diagnosed (so far 32), with small mutations very
frequent (42% in DMD and 34% in BMD) compared to
large rearrangements.March 2020 | Volume 11 | Article 131
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Therapies
In our cohort, the percentage of DMD patients eligible for stop
codon reversion therapy was 14.4%. We also explored the stop
codon type (TGA, TAA, TAG) occurring in DMD. All three
nonsense codons were present in the mutational scenario,
however regional differences occurred (Supplementary Figure
2). In the North region, the three stop codons were equally
present in mutated DMDs, while in the South and in Sicily half
(49%) of DMD patients carried the TGA stop codon. In the
Center, the TAA stop codon was poorly represented (13%). In
Sardinian patients, the TAG stop codon was not present.
The trend in BMD patients in the North, in the South and in
Sicily was very similar to DMDs, while in the Center only TAA
stop codons occurred. Sardinian BMD patients showed only
TGA stop codons.
In our Italian cohort, the percentage of DMD patients eligible
for exon skipping was 63% of the patients with out-of-frame
deletions; among these, 17.8% was eligible for exon 53 skipping,
17% for exon 51, 11.4% for exon 44, 16.6% for exon 45. There
were some regional differences (Supplementary Figure 3). The
North and Center regions showed very similar percentages of
skipping amenability, with the exon 53 skipping being the most
frequently skippable exon, and the South and Sicily had a
different pattern, with exon 45 being the predominantFrontiers in Genetics | www.frontiersin.org 7skippable exon. In Sardinian patients, only those eligible for
exon 44 skipping were found.
Table 2 and Figure 4 show an overview of genotype data of
our cohort compared to the two previously reported
nationwide studies.DISCUSSION
Rare Diseases (RDs) represent a major challenge worldwide, with
many initiatives devoted to achieving an appropriate genetic and
clinical diagnosis launched in many countries (http://www.
udninternational.org). Early and accurate genetic diagnosis is
recommended by all guidelines and is now considered
compulsory for mutation identification, allowing for
prevention and family planning, and applies to all
dystrophinopathy mutation groups (Koeks et al., 2017).
In addition, the emergence of new therapeutic and often
personalized approaches in DMD has further highlighted the
need for an early genetic definition in order to identify eligible
patients. Many of the new drugs are mutation-specific or gene-
specific, e.g. nonsense mutations for stop-codon read-through or
frame-shift deletions for exon skipping and gene therapy, which
also requires a genotype definition (Cirak et al., 2011; McDonald
et al., 2017).FIGURE 2 | Small mutations distribution in in-frame or out-of-frame exons in DMD and BMD patients. The majority of small changes in DMD (68.5%, n=211) locates
in out-of-frame exons, while only 31.4% (n=97) locates in in-frame exons. Nonsense mutations occur in 62% in-frame exons compared to 51% in out-of-frame
exons, frameshifting changes are more frequent in out-of-frame exons and the missense are 2% in in-frame vs 6% out-of-frame. In BMDs, small changes are
prevalent in in-frame exons (58.3%, n= 42) compared to out-of-frame (41.6%, n=30) exons. Nonsense mutations occur much more frequently, almost double, in in-
frame exons (57% vs 30%), frameshifting changes are equally distributed (17%) and missense mutations are more represented in out-of-frame exons (53% vs 19%).March 2020 | Volume 11 | Article 131
Neri et al. DMD Gene Mutations in ItalyIn order to define the mutational landscape in Italian DMD
and BMD patients, we retrospectively collected (January 2008-
December 2017) genetic data from 11 diagnostic Italian
Reference Centers, identifying a total of 1902 patients carrying
a DMD mutation. Mutation detection methods were rather
homogeneous, invariably based on CNV detect ion
predominantly by MLPA (9/11 centers), followed by sequencing
(11/11 centers) via NGS techniques (either gene-specific or based
on gene panels); all centers also used Sanger sequencing for
mutation validation or in patients diagnosed before the
availability of NGS approaches.
DMD Deletions and Duplications:
Frequency, Distribution, Topography
In our Italian cohort, mutation-type frequency substantially
overlaps those already published in other patient cohorts, with
some peculiarities. DMD patients have 57% of deletions and 11%
of duplications, which is slightly lower compared to other
European studies reporting deletions of more than 60% and of
duplications of more than 10% (Tuffery-Giraud et al., 2009;
Bladen et al., 2015) .
In a Chinese study, the percentage of rearrangements in
DMD patients is similar to ours, with 60% of deletions andFrontiers in Genetics | www.frontiersin.org 89.6% of duplications (Guo et al., 2015) while in an Indian cohort
(Polavarapu et al., 2019) there was a higher prevalence of
deletions (80%) and only a small percentage of duplications
(5%) with a complete absence of the most common exon 2
duplication. In a very large sample population of United
Dystrophinopathy Project, Flanigan et al. (2009) reported a
43% percentage of deletions and 11% of duplications in all the
dystrophinopathy patients (including DMD, BMD, and
intermediate phenotypes); the low percentage of deletion
compared to the one reported in literature is discussed as due
to a selection bias. This heterogeneous mutation scenario
supports the existence of population or ethnic differences,
which have to be taken into account when planning country-
specific genetic screening or even therapeutic approaches.
Among all dystrophinopathies, the most frequent multiple
exons deletion is 45 to 52, while it was 45 to 50 in the French
population (Tuffery-Giraud et al., 2009). These two major
deletion events therefore share the 5′ breakpoint in intron 44
but not the 3′ breakpoint, which lies in intron 52 for the Italian
and in intron 50 for the French patients. Again, these two introns
(50, 45782 bp and 52, 50044 bp, quite similar in length) might
have genetic differences in the two populations. Remarkably,
blast analysis of the two introns revealed an anti-oriented 87%FIGURE 3 | Geographical distribution of mutations based on the place of birth of DMD and BMD patients. Nonsense mutations account for only 6% in the South
compared to 20% in the North, with the counterpart of frameshifting changes being 8% in the North and 16% in the South. Sardinian patients show a very different
mutation spectrum.March 2020 | Volume 11 | Article 131
Neri et al. DMD Gene Mutations in Italyhomology in 861 bps. Four (T)n(A)n, motif-rich regions can be
seen, one of these being an exact TTTAAA in intron 50, but not
in intron 52 (TTAAAA) (Supplementary Table 3). This motif is
known to lead to micro-homology recombination events. It
might be hypothesized that population-specific SNP(s) within
this motif in intron 52 may modify its rearrangement propensity.
Distribution of deletions in our patient cohort confirms the
two well-known hot spots at the 5′ end (surrounding exon 3–7)
and the broader region at the 3′ end of the gene involving exons
45 to 54. Since the more frequently deleted exon is 45 (either as
single exon deletion or in multiple deleted exons interval), it
means the vast majority of DMD deletions have the 5′ breakpoint
in the huge intron 44 (248401 bp), apart from very rare cases
with the breakpoint within the exon 45 itself. This is quite
consistent with the Tuffery (Tuffery-Giraud et al., 2009) and
Bladen (Bladen et al., 2015) reports. Introns 1 (whose genomicFrontiers in Genetics | www.frontiersin.org 9annotation is promoter-specific depending on the brain, muscle,
and Purkinje full-length isoform driving sequences), 7 and 44 are
the largest DMD introns, a phenomenon known as intron
gigantism, which is quite frequent in vertebrates (Pozzoli et al.,
2003). Although it is unknown why intron gigantism occurs,
large introns are thought to function as “providers” of regulatory
regions or new exons (exon shuffling), which might confer
evolutionary advantages to genes from one side, but cause high
recombination rates via non homologous recombination, from
the other (Rogozin et al., 2005). It is also known that out-of-
frame exons are separated by significant longer introns
compared to in-frame exons, as clearly evident in the DYS
rod-domain, a large region from exon 23 to exon 42 where all
exons are in-frame and separated by shorter introns (average of
22.400 bp, ranging from 309 bp of intron 35 to 31823 bp of
intron 41) (Pozzoli et al., 2002). Indeed the 1, 7, and 44 giantTABLE 2 | Mutation distribution in Duchenne and Becker patients of our cohort compared to previously published cohorts.
Phenotype DMD Mutations Bladen et al., 2015 Tufferey-Giraud et al., 2009 Italian network Mean value
ALL DYSTROPHINOPATHIES
(MALES, CARRIERS)
7149 2084 1902
LARGE REARRANGMENTS 80% 77% 75,2% 77,4%
SMALL 20% 22,3% 24,7% 22,3%
DELETIONS 68% 67.4% 65,2 % 66,8%
DUPLICATIONS 11% 10.3% 9,9 % 10,4%
FRAMESHIFTING (7%) 7.0% 7,3% 7,15%
SPLICING 3% 5,9% 4,6% 4,5%
NONSENSE 10% 8,8% 10,5% 9,7%
MISSENSE (1%) 0,6 2% 1,2%
DUCHENNE 1315 1162
LARGE REARRANGMENTS 74% 67,9% 70,9%
SMALL 26% 32% 29%
DELETIONS 61,5% 57,4% 59,4%
DUPLICATIONS 13% 10,5% 11,7%
INDELS 8,3% 10,9% 9,6%
SPLICE 4% 6,1% 5%
NONSENSE 12,1% 14,2% 13,15%
MISSENSE 0.9% 1,2% 1%
Most single exon deletion 45 (7, 4%) 45 (4%)
Most multiexon deletion 45–50 (5,8%) 45–52 (3,2%)
Most single exon duplication 2 (9,8%) 2 (13%)
Most multiple exon duplication 3–7 (5.1%) 3–7 (4,7%)
BECKER 560 740
LARGE REARRANGEMENTS 86,8% 86,86 86,8%
SMALL 13,2% 13,14 13,1%
DELETIONS 80,7 77,8 79,2%
DUPLICATIONS 6% 9,06 7,5%
INDELS 2% 1,66 1,8%
SPLICING 7,2% 3,38 5,29
NONSENSE 3,1% 4,46 3,78
MISSENSE 0,5% 3,24 1,87%
Most single exon deletion 48 (3,5%) 48 (4,7%)
Most multiexon deletion 45–47 (29%) 45–47 (5.9%)
Most single exon duplication None 3 (1%)
16 (1%)
Most multiple exon duplication 2–7 (2.8%) 3–16 (2.6%)
19–41 (2.6%)March 2020 | Volume 11 | Article 131
Neri et al. DMD Gene Mutations in Italyintrons are just downstream of out-of-frame exons (1, 7, and 44),
which are (not surprisingly) the DMD deletion hot spots. These
three introns are also very rich in short tandem repeats
(especially TTTAAA or (T)n(A)n), which are known to cause
aberrant firing of the replication fork, as frequent mechanisms
responsible for micro-homology related recombination events
(Marey et al., 2016). We would like to underline that these three
exons are the upstream exons of regions encoding extremely
important DYS domains: the actin binding domain (exon 1,
although possibly dispensable, as suggested by Wein et al., 2014),
the Hinge 1 (exon 7) and the nNOS binding domain, involved in
DYS signaling functions (Rybakova et al., 2000). Also Hinge2
and Hinge3 domains are encoded by out-of-frame exons such as
17 (intron length 35.892 bp) and 50 (intron length 45.764 bp). It
is quite likely that these large introns had relevant impact on the
evolution of the human DMD gene leading to the acquisition of
new functions. Recently, new DMD microgenes designed for
gene therapy and inclusive of Hinge 1, Hinge 2 and nNOS
domains resulted more functional in mice (Ramos et al., 2019).
Based on this knowledge, it might be important to carefully
define deletion intervals by annotating intronic breakpoints to
better understand how a different genomic architecture or even
locus rearrangements may impact on RNA transcription, protein
translation machinery, and clinical outcome. This might also be
relevant in optimizing gene therapy approaches. More generally,
introns deserve more studies in order to investigate and define
their functions in the DMD gene context. The availability of
WGS will certainly facilitate this task in the very near future.Frontiers in Genetics | www.frontiersin.org 10Analyzing our mutation scenario, both in DMD and BMD, 29
in-frame exons (exons 3, 4, 9, 15, 16, 23, 25, 26, 28, 29, 32, 33, 34,
35, 36, 37, 38, 39, 41,42, 49, 60, 64, 71, 72, 73, 74, 75, 79) are never
the site of single exon deletion. This is interesting data, never
having been investigated in other reports. Possible
interpretations are that these exons do not belong to regions
susceptible to mutational events or, conversely, that single
deletions occurring in these in-frame exons might not be
pathogenic, thus causing asymptomatic or very mildly-affected
individuals only. These cases may have escaped genetic definition
since diagnostic tests are generally only performed on
symptomatic patients. This second hypothesis seems to be
supported by the consistency of this finding in BMD as well,
where we would expect in-frame deletions leading to milder
phenotypes. Interestingly (but not surprisingly), the majority
(85%) of “never singly deleted” exons belong to the large rod-
shaped protein domain (R, where 3′-R6 to 5′-R16 or spectrin-
like tandem repeats) encoded by the long sequel of in-frame
exons 23 to 42. Among the “never singly deleted” in-frame exons,
exons 3, 16, 29, and 41 are also never singly duplicated,
supporting their possible dispensability for the DMD gene
essential functions.
Combining this last consideration with previous observations,
it might be that the central DYS rod-shaped domain is not
entirely necessary for the protein anchorage function, however it
may influence other protein functions not directly related to the
structural DYS role at the sarcolemma, but may also be more
relevant for other non-muscle compartments. Indeed, a deepFIGURE 4 | Mutations distribution in DMD and BMD patients from Italy compared to literature data. Overview of genotype data of our cohort in comparison to
previously reported other nationwide studies. Tuffery-Giraud et al. (2009). Hum. Mutat. 30, 934-45; Bladen et al. (2015). Hum. Mutat. 36, 395-402.March 2020 | Volume 11 | Article 131
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deletion types might help to better understand the DYS
protein domains preservation consequences and residual
functions both in striated muscles and other tissues, like for
instance, the brain.
Duplications occur at similar frequencies in DMD (11%) and
BMD (9%) as described in other reports, and they are distributed
anywhere along the gene, though 42% involve the 5′ hot spot
between introns 1 and 9, according to literature data (Aartsma-Rus
et al., 2017); themost common single exon duplication is exon 2, in
agreement with previous literature data (Wein et al., 2014).
Single exon duplication hot spots have major 5′ breakpoints
within Dp427 muscle isoform intron 1 and intron 2, while
multiple exon duplications do have the major sites within
intron 2 (upstream) and intron 7 (downstream). Therefore,
both deletions and duplications recognize their breakpoints in
giant introns 1 and 7, but not intron 44, where duplication
breakpoints rarely locate. This is also an interesting finding since
mechanisms underlining deletion and duplication events are
different indeed. Deletions seem to be frequently related to
micro-homology in breakpoint regions, mainly due to the
presence of short tandem repeats, interspersed repeat elements
which can predispose to deletion events (Esposito et al., 2017) or
(as already mentioned above) due to an aberrant firing
replication fork. Duplications are known to arise from either
homologous (such as Alu-Alu) recombination or non-
homologous recombinat ion, which is mediated by
topoisomerases activity. Some papers describe, in detail, DMD
duplications mainly as intra-chromosomal and propose that
unequal sister chromatid exchange might be the major
mechanism (Worton, 1992). It is known that segmental
duplication was found to be associated with rapid primate gene
evolution and chromosomal rearrangement (Samonte and
Eichler, 2002). Notably, duplications (but not deletions)
occurred at a similar rate in DMD (11%) and in BMD (9%)
patients, in all cohorts, supporting a common underlining
mutational mechanism, irrespective of the phenotype.
Finally, deletions and duplications might be primed by
preexisting small indels or point mutations, which may elicit
the rearrangement events via attempts to correct preexisting
mutations, as we speculated above for intron 50 and 52 (Oshima
et al., 2009). In this context, full intron sequencing, via WGS
strategy, will have a tremendous impact on the understanding of
DMD rearrangement mechanisms, and the occurrence of the
many known synonymous changes (SNPs) in the gene may find
novel avenues for interpreting their functional meaning.
BMD patients show an 87% of gross rearrangements (deletion
and duplication), strongly suggesting that they must be first
approached by CNV detection during the diagnostic flowchart
and not by sequencing. Indeed, a false perception of “negative
results” may come from a negative NGS test done in BMD
patients, a fact that may delay or even hamper the clinical
diagnosis. Moreover, the majority of large DMD rearrangements
involve multiple exons, implying that deletion/duplication
detection should be done by exploring all exons, and therefore
using fully accurate techniques.Frontiers in Genetics | www.frontiersin.org 11Small Mutations Frequency, Distribution,
and Types
The rate of small mutations in the Italian DMD cohort is 32%,
higher than those reported by other papers. Differently from
gross rearrangements, small mutations are randomly distributed
along all exons without hot spots, and the majority of them are
“private,” contributing to the tremendous allelic heterogeneity
of dystrophinopathies.
Small mutation-type frequency is a bit more articulated
compared to other reported data. In both DMD and BMD,
nonsense changes are 14% and 5% respectively, thus the most
frequent small variant-type occurring in Italian patients. As a
peculiarity, Italian BMD have 3% of missense mutations, which
is a rather high percentage, compared to DMD or other
published cohorts. Indeed, the pathogenicity of missense
mutations (generally, and not only in DMD/BMD) needs
robust evidence like, for instance, being previously reported in
databases or confirmed by functional studies or robust in silico
prediction, following the pathogenicity scale recommendations
of the American College of Medical Genetics and the European
Society of Human Genetics (Richards et al., 2015). The large
number of BMDs diagnosed in our cohort may justify the high
number of missense mutations identified. Indeed, the BMD
phenotype may need to be clinically differentially diagnosed
with many LGMDs (Vissing, 2016), or alternatively it might be
very mild, even escaping a clinical diagnosis and consequently
the DMD genetic testing.
It has been hypothesized that small changes occurring in in-
frame exons may cause milder phenotypes via spontaneous exon
skipping of the mutated exon, which may elide (to some extent
and in a quantitative manner) the mutation consequence.
Indeed, the majority of small changes (all types) in our DMD
Italian patients localizes in out-of-frame exons (68.5%, N = 211
vs 31.4% N = 97 in in-frame exons), therefore predicting a
general low self-reframing capability. Specifically, according to
the self-framing capability rule, nonsense variants occur in 62%
of in-frame exons compared to 51% in out-of-frame exons,
frameshifting changes are more frequent in out-of-frame exons
(43% vs 36% in-frame ) and missense are 2% in in-frame vs 6%
out-of-frame.
In BMDs, small changes are slightly prevalent in in-frame
exons (58%, n = 42) compared to out-of-frame (42%, n = 30)
exons. Interestingly, nonsense mutations occur much more
frequently in in-frame exons (57% vs 30%), frameshifting
changes are equally distributed (both being 17%) and missense
mutations are significantly more represented in out-of-frame
exons (53% vs 19%).
The “small-in-frame” trend for small mutations in BMD
partially applies for nonsense changes, which might sometimes
account for the milder phenotype of BMD carrying a single
premature stop codon in an in-frame exon that can be favorably
skipped. The in-frame exon might indeed be able to self-reframe
dystrophin by endogenous skipping, leading to an ameliorated
phenotype. Nevertheless, the “small-in-frame” trend does not
meaningfully apply for missense mutations, as hypothesized by
some authors, and therefore it is not expected to play a crucialMarch 2020 | Volume 11 | Article 131
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that self-correcting exon skipping may involve more than one
exon and in this case prediction of phenotype effect based on
small mutations location is not possible (Aartsma-Rus et al.,
2016). This is even more true for splicing mutations for which it
is not possible to predict “a priori” the precise effect on skipping
and therefore on self-reframing and phenotypic outcome.
It should be also mentioned that single nucleotide changes
might alter the complex process of exon recognition by the
splicing machinery, via weakening the exonic splicing enhancers
(ESEs), for which identification in vitro studies are needed
(Tuffery-Giraud et al., 2017).
Regional Data
The high genetic heterogeneity of the Italian population is well
known and widely reported (Chiang et al., 2018). DMD
mutation-type distribution in the North and South regions is
overall similar, with some remarkable differences (Figure 3).
Nonsensemutations account for only6% in theSouth compared
to the 20% in the North, with the counterpart of frameshifting
changes being 8% in the North and 16% in the South. This is a new
finding in theDMD gene. It is very well known thatmutation types
vary greatly in different ethnic groups, as documented for many
autosomal recessive diseases (Rohlfs et al., 2011). Indeed, the
heterogeneous mutation scenario, for instance in cystic fibrosis
(worldwide), has led to mutation-specific diagnostic approaches in
some regions and has addressed diagnostic flowcharts with
implications in mutation-driven newborn screening procedures
(Bosch et al., 2017). Mutagenic mechanisms underlining point
mutations and frameshifting changes are also different, since
single nucleotide substitutions are more often caused by DNA
replication errors or proofreading failure Ankala et al., 2012), while
frameshifting changes are due to imperfect inverted repeats which
cause a deletion or a tandemduplication of the flanking nucleotides
(Todorova and Danieli, 1997). Therefore, it is not surprising that
genetic background may play a role in small mutation
occurrence diversity.
Sardinian patients show a very different mutation spectrum.
Deletions are only 35% in DMD and 46% in BMD, and small
mutations are very frequent (42% in DMD and 34% in BMD).
Although data may suffer with the low number of residential
patients diagnosed (so far 31), the concordant percentage
between DMD and BMD suggests that the trend may reflect
the ethnic peculiarity of Sardinia (Chiang et al., 2018).
We have also analyzed the stop codon types (TGA, TAA, TAG)
in all nonsense mutations identified in our patients (N = 200)
(Supplementary Figure 2). The three codons are almost equally
represented in the mutation spectrum (national average). However,
regional distribution showed that in the North and Center regions,
this trend is maintained with TAG slightly more frequent (38%
North, 47% Center). In the South and Sicily, the TGA codon is the
most frequent nonsense occurring mutation (49%).
Sardinian DMD show only TGA and TAA nonsense codons,
while in BMD only the TGA codon (100%) was found. This very
peculiar behavior supports, again, a role of ethnic background in
mutagenesis and DMD gene mutation occurrence andFrontiers in Genetics | www.frontiersin.org 12distribution (Tian et al., 2008), which would really deserve
further studies. Alternatively (but possibly concomitantly), the
known phenomenon of codon usage bias, meaning that some
synonymous/stop codons are negatively selected through
evolution, may play a role in the different regional nonsense
mutation types occurrence since, obviously, nonsense mutation
types depend on the native codon in the permutated sequence
(Hanson and Coller, 2018).
Therapeutic Implications
In our Italian cohort the percentage of DMD patients eligible for
stop codon reversion therapy (such as Translarna) is 14.4%.
The other personalized therapeutic approach is based on
antisense oligoribonucleotides (AONs) aimed at inducing
favorable, dystrophin-reframing, exon skipping (Aartsma-Rus
et al., 2017). Different backboned AONs are currently in use,
either in clinical trials (see in ClinicalTrials.gov) or even
designated as orphan drugs such as Eteplirsen, or Exondys51,
which induces the DMD exon 51 skipping in amenable patients
(Syed, 2016). Other molecules that induce the skipping of exon
44, 45, and 53 are also currently in clinical trials.
In our Italian cohort, the percentage of DMD patients eligible
for exon skipping (all 4 amenable exons) is 63% among all out-
of-frame deletions, with (in percentage order) 17.8% eligible for
exon 53, 17% for exon 51, 16.6% for exon 45 and 11.4% for exon
44 skipping. Similarly to the nonsense mutation type, skipping
eligibility also shows some regional differences. The most
frequently skippable exon is exon 53 in the North and Center
regions and exon 45 in the South and in Sicily. In Sardinian
patients, only exon 44 skipping is applicable in the currently
diagnosed DMD patients.CONCLUSIONS
Our large and nationwide DMD gene mutation report (so far the
first published in Italy) revealed that mutation types as gross
categories (rearrangements and small mutations) overlap in
terms of frequency with those of other similar reports, but
mutation-type frequency differences are also present, even at a
regional level, where ethnicity may play a role in mutation
diversity. We analyzed deletions and duplication intervals in
detail and suggest that the genomic rearrangement mechanisms
underlining the two events are different. This complexity
suggests the need for a finer genetic characterization in DMD
and BMD patients (full genome sequencing might be in the near
future), especially to better address drug design and understand
the outcome of gene specific therapies.
From the deletion data it has emerged that some exons might
be dispensable and some “asymptomatic” cases may carry these
“invisible” DMD deletions. A systematic search for incidental
findings occurring in these exons might be essential, as it could
reveal the true frequency of these “healthy” events. Knowing if
some DMD exons are definitively dispensable for a DYS protein
full function would have a tremendous impact on gene
therapy design.March 2020 | Volume 11 | Article 131
Neri et al. DMD Gene Mutations in ItalySmall mutations are very frequent in the DMD Italian cohort
patients, but rarer in BMD. This is also an important finding,
addressing CNV identification as a priority within the diagnostic
approach, especially in BMD. Finally, the “small-in-frame” trend
does not widely occur for small mutations in BMD, apart from,
although partially, nonsense changes, and therefore understanding
why detrimental small mutations do cause DMD or BMD
phenotype needs further investigation.
We believe that reporting data on such a large patient cohort
might be extremely valuable for many aspects, from
etiopathogenesis to therapy, as a large number of patients can
allow for a better understanding of disease mechanisms and
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SUPPLEMENTARY FIGURE 1 | Exonic distribution of deletions and duplications
in DMD and BMD patients DMDs have 57% of deletions and 11% of duplications.
The most common single exon deletion in DMD is exon 45 while the most common
multiple exon deletion is 45-52. Deletions were non-randomly distributed, occurring
in the two known hot spots at the 5’ and 3’ end of the gene and very
heterogeneous.
SUPPLEMENTARY FIGURE 2 | Geographical distribution of nonsense codons
in DMD and BMD patients The three codons are almost equally represented in the
national mutation spectrum; regional distribution showed that in Northern and
Central regions this trend is maintained with TAG slightly more frequent than the
others (38% North, 47% Center). In Southern and Sicily the TGA codon is the more
frequently occurring nonsense mutation (49%). Sardinian DMD show only TGA and
TAA nonsense codons, while in BMD only the TGA codon (100%) was found.
SUPPLEMENTARY FIGURE 3 | Geographical distribution of skippable deletions
in DMD patients Northern and Central regions show very similar percentages of
skippability, being the exon 53 the more frequently skippable exon, South and Sicily
have a different pattern being exon 45 the predominant skippable exon. In Sardinian
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